A phase I study evaluating the safety and immunogenicity of a new TB vaccine, MVA85A, in healthy volunteers who are latently infected with Mycobacterium tuberculosis
Latest Information Update: 10 Nov 2021
Price :
$35 *
At a glance
- Drugs MVA 85A (Primary)
- Indications Tuberculosis
- Focus Adverse reactions
- 16 Jun 2007 New trial record.